Isolated and purified human soluble guanylyl cyclase .alpha.1/.beta.1 (hsgc .alpha.1/.beta.1)
CA 2339529 C · Owner: Zabel, Ulrike · Inventors: Poller, Wolfgang; Zabel, Ulrike; Schmidt, Harald
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The invention relates to the expression of the cDNA clone for sub-units a1 (hsGCa1) and b1 (hsGCb1) of human soluble guanylylcyclase and the subsequent purification of the active enzyme and use thereof the medical application of , the expression of this clone by gene transfer in addition to antibodies , against peptides derived from said sequence and the use thereof.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed August 16, 1999 and granted April 24, 2012. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended August 16, 2019.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by August 16, 2021.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.